Creon (AbbVie Inc.)


Welcome to the PulseAid listing for the Creon drug offered from AbbVie Inc.. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: AbbVie Inc.
NON-PROPRIETARY NAME: Pancrelipase
SUBSTANCE NAME: PANCRELIPASE AMYLASE; PANCRELIPASE LIPASE; PANCRELIPASE PROTEASE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS:
ROUTE: ORAL
DOSAGE FORM: CAPSULE, DELAYED RELEASE
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2009-04-30
END MARKETING DATE: 0000-00-00


Creon HUMAN PRESCRIPTION DRUG Details:

Item DescriptionCreon from AbbVie Inc.
LABELER NAME: AbbVie Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 15000; 3000; 9500([USP’U]/1; [USP’U]/1; [USP’U]/1)
START MARKETING DATE: 2009-04-30
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0032-1203_c1fc1c81-d34a-7baf-ba5c-48425e015fe1
PRODUCT NDC: 0032-1203
APPLICATION NUMBER: NDA020725

Other PANCRELIPASE AMYLASE; PANCRELIPASE LIPASE; PANCRELIPASE PROTEASE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AbbVie Inc.Creon